top of page
color-adjusted-background-3.png

Pioneering Multi-functional Therapeutics for Neurodegenerative Diseases

Innovative chemistry platform to generate first-in-class small molecules modulating three known processes involved in neurodegeneration: protein misfolding, oxidative stress and neuro-inflammation

Our Trojan Horse

Ilios is the ancient name of Troy. Our Trojan Horse delivers multi-functional drugs to the brain to combat neurodegeneration.

Multi-functional
Small Molecules

Modulating three known disease processes: protein misfolding, oxidative stress and neuro-inflammation

Novel Chemistry, Validated Agents

Merging privileged bioactive pharmacophores with glutathione and fatty acids to create proprietary brain-penetrant small molecules

Intelligent Drug Discovery

Ilios’ proprietary library of compounds is a cutting-edge machine learning training set to generate novel therapeutics

Modular
Platform

Facilitating rational design of treatments for multi-factorial diseases, including ALS, Frontotemporal Dementia, Parkinson's, and Alzheimer's Disease

Novel approach to neurodegeneration

Modulate multiple complementary mechanisms with a single drug 

First in class small molecules optimized to module three known processes that play a key role in neurodegeneration: protein misfolding, oxidative stress, and neuro-inflammation

Presentation1.png
slide2-5.png
Synergistic activity in rationally designed NCEs merging validated naturally occurring ligands

Our modular chemistry platform merges bioactive pharmacophores with Glutathione and Fatty Acids to create New Chemical Entities (NCEs). These are designed to synergistically modulate multiple mechanisms involved in neurodegeneration   

Delivering superior molecules using an innovative med-chem approach
  • Chemistry platform and lead program de-risked by decades of research

    • Components have demonstrated activity against protein misfolding, oxidative stress and neuro-inflammation

    • Merging ligands overcomes efficacy and drug-like property limitations of individual components

    • No novel biology: three processes targeted are known drivers of disease pathophysiology

  • On track to deliver lead candidate by H1 2025

Our first indication is ALS
slide3-2.png
bottom of page